APASL Criteria for ACLF
The APASL (Asian Pacific Association for the Study of the Liver) criteria identify ACLF at an early, sensitive stage and require: acute hepatic insult manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin time ≤40%), complicated by ascites and/or hepatic encephalopathy within 4 weeks, in patients with previously diagnosed or undiagnosed chronic liver disease. 1, 2
Core Diagnostic Components
The APASL definition differs fundamentally from other regional criteria by capturing patients earlier in the disease trajectory:
Patient Population
- Applies to patients with chronic liver disease with or without cirrhosis
- Includes patients with no prior decompensation (compensated cirrhosis)
- Also encompasses non-cirrhotic chronic liver disease 3, 2
Required Hepatic Dysfunction
- Serum bilirubin ≥5.0 mg/dL (jaundice)
- Coagulopathy: INR ≥1.5 OR prothrombin time ≤40% of standardized values
- These parameters must develop within 28 days after acute insult 4, 2
Required Complications
Development of ascites and/or hepatic encephalopathy within 4 weeks of jaundice onset 2
Precipitating Events (Acute Insults)
APASL traditionally emphasized intrahepatic precipitants:
- Alcohol abuse
- Viral hepatitis exacerbation (particularly HBV reactivation)
- Drug-induced liver injury
- Autoimmune hepatitis flare
Important caveat: The updated 2019 APASL consensus expanded to include gastrointestinal bleeding and bacterial infections as precipitants, though this remains a point of distinction from the original definition 4, 2
Clinical Context and Limitations
Sensitivity vs. Specificity Trade-off
The APASL criteria are highly sensitive but not specific - they identify patients early when intervention may be most effective, but most patients meeting these criteria will not die by day 28 (mortality <30%) 1. This contrasts sharply with EASL-CLIF (intermediate stage, 30-50% mortality) and NACSELD (late stage, >50% mortality) definitions 1.
The "Golden Therapeutic Window"
APASL's early identification creates a critical therapeutic window where aggressive management of precipitants and organ support may reverse the syndrome before irreversible multi-organ failure develops 2
Grading System
The Japanese adaptation proposed four severity grades based on extent of organ dysfunction (liver, kidney, brain, coagulation, circulation, respiration), allowing risk stratification within APASL-defined patients 4
Key Distinguishing Features
What APASL excludes that other definitions include:
- Does not require extrahepatic organ failure for diagnosis (unlike EASL-CLIF and NACSELD) 1, 3
- Originally excluded bacterial infection as precipitant (now included in updated criteria) 3, 2
- Does not apply to patients with prior decompensation in original definition 3
What makes APASL unique:
- Focuses on acute liver injury severity rather than multi-organ failure
- Emphasizes reversibility potential through early identification
- Particularly relevant in Asia-Pacific regions where HBV-related acute flares are common 2
Practical Application
When evaluating a patient for APASL ACLF, confirm:
- Chronic liver disease documented (any etiology, cirrhotic or non-cirrhotic)
- Acute insult identified within past 4 weeks
- Laboratory criteria met: Bilirubin ≥5 mg/dL AND INR ≥1.5
- Clinical decompensation: New ascites or encephalopathy
- Timeline: All parameters developed within 28 days
Critical pitfall: APASL criteria will capture many patients who would be classified as "acute decompensation without ACLF" by EASL-CLIF criteria, as extrahepatic organ failure is not required 1, 3. This explains why APASL-defined ACLF has lower short-term mortality than other definitions - it identifies an earlier disease stage 1, 5.